ERBB2 and breast carcinoma: This demonstrates that the CEER technology can be used to detect activation of ErbB receptors in samples obtained from both HER2 gene amplified and non-amplified breast cancer systems including limited amounts of tumor tissue isolated through minimally invasive FNA procedures.